← Back

TriSalus Life Sciences Inc.

TriSalus Life Sciences, Inc. is a healthcare company focused on the research, development, and commercialization of drug delivery technology and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. Its offerings include Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system used in transarterial radioembolization and chemoembolization procedures for liver cancer and metastases, and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trials for locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trials for uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. Founded in 2009 and headquartered in Westminster, Colorado, TriSalus serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff.

Country
Price · split & dividend adjusted
News & notes moving TLSI
TLSI▲

TriSalus Life Sciences Q2 Revenue Rises 1.7% to $11.4 Million, Reiterates 2026 Outlook

TriSalus Life Sciences reported second-quarter revenue of $11.4 million, a 1.7% increase from $11.2 million a year earlier, and reiterated its full-year 2026 revenue forecast of $54 million to $57 million. The company more than doubled its commercial footprint in the first half of the year, with all new sales representatives in place by April. A new CMS G-code could extend reimbursement for the TriNav pressure-enabled drug delivery system into physician office-based labs, potentially supporting growth in liver, uterine, prostate, and genicular artery embolization procedures. Gross margin improved to 86.8% from 83.9%, but higher sales and marketing costs from the expanded sales force widened the adjusted EBITDA loss to approximately $7.1 million from $5.3 million. TriSalus ended the quarter with about $46.3 million in cash and expects sequential revenue improvement in the second half of 2026.
TLSI ▲
MarketBeat·42dRead more →
TLSI▼

Schall Law Firm Investigates TriSalus Life Sciences for Securities Law Violations

The Schall Law Firm has launched an investigation into TriSalus Life Sciences, Inc. for potential securities law violations. The investigation centers on whether the company made false or misleading statements or failed to disclose material information to investors. TriSalus reported its first-quarter financial results on May 12, 2026, revealing a year-over-year quarterly revenue decline of more than 2.9% and a cut to its full-year revenue guidance. The company attributed the revision to lower first-quarter revenues from commercial expansion and a delay in FDA clearance for its TriNav Advance device, which is now running approximately five months past the 30-day MDUFA review goal.
TLSI ▼
GlobeNewswire·93dRead more →
© 2026 MarketDXAsset